CLAIMS:

1. A liquid pharmaceutical composition comprising:

(a) adalimumab;

(b) an acetate buffering agent or acetate buffer system; and

(c) a sugar stabiliser selected from the group including trehalose, sucrose, maltose, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, and inositol;

wherein the composition is either substantially or entirely free of arginine or comprises arginine in a concentration of at most 0.1 mM; and

wherein the composition is either substantially or entirely free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM.

2. The liquid pharmaceutical composition as claimed in claim 1, wherein the composition further comprises an acid/base conjugate of the buffering agent such that together the buffering agent and its acid/base conjugate are present at a level and in a relative amount sufficient for the composition to have a pH between pH 5.0 and 5.5, wherein the acetate buffering agent is sodium acetate and the acid/base conjugate is acetic acid.

3. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the sugar stabiliser is trehalose.

4. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition is either substantially or entirely free of amino acids or comprises one or more amino acids in a collective concentration of at most 0.1 mM.

5. The liquid pharmaceutical composition as claimed in claim 4, wherein the composition is free of amino acids.

6. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition is either substantially or entirely free of surfactants, with the optional exception of polysorbate 80, or comprises one or more of surfactants, optionally excluding polysorbate 80, in a collective concentration of at most 0.001 mM.

7. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition is substantially or entirely free of polysorbate 20.

8. The liquid pharmaceutical composition as claimed in any preceding claim, further comprising a tonicifier selected from sodium chloride, potassium chloride, magnesium chloride, or calcium chloride.

9. The liquid pharmaceutical composition as claimed in any preceding claim, further comprising polysorbate 80.

10. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the osmolality of the composition is between 220 and 400 mOsm/kg.

11. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the protein unfolding temperature of adalimumab in the liquid pharmaceutical composition is greater than or equal to 70^{o}C.

12. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises adalimumab, acetate buffering species, and trehalose in a weight ratio of 25-75 : 0.12-3.0 : 15-140 respectively.

13. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises adalimumab, acetate buffering species, trehalose, and sodium chloride in a weight ratio of 45-55 : 0.30-0.84 : 65-72 : 2.7-3.1 respectively.

14. The liquid pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises:

- 45 to 55 mg/ml adalimumab;
- 5 to 14 mM sodium acetate/acetic acid buffer system;
- 190 to 210 mM trehalose;
- 40 to 60 mM sodium chloride;
- 0.9 mg/mL to 1.1 mg/mL polysorbate 80; and
- water for injection;
- wherein the composition:
    - has a pH between between 5.1 and 5.3;
    - is free of arginine or comprises arginine in a concentration of at most 0.001 mM;
    - is free of amino acids or comprises one or more amino acids in a collective concentration of at most 0.001 mM.

- o is free of surfactants with the exception of polysorbate 80 or comprises one or more of said surfactants excluding polysorbate 80 in a collective concentration of at most 0.0001 mM; and/or
- o is free of phosphate buffering agents, e.g. sodium dihydrogen phosphate, disodium hydrogen phosphate, or comprises a phosphate buffer system in a concentration of at most 0.001 mM.

15. A drug delivery device comprising a liquid pharmaceutical composition as claimed in any preceding claim.

16. A liquid pharmaceutical composition as claimed in any of claims 1 to 14 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis.